Papillary Thyroid Carcinoma

Erickson, Lori A.

doi:10.1007/978-1-4939-0443-3_5

Cited by 2 publications

(2 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, two low-frequency CC>TT tandem variations have been described at positions 1295228/1295229 (−124/-125 from the ATG site) and 1295242/1295243 (−138/-139 from the ATG site), which were named C228T/C229T and C242T/C243T, respectively ( 13 , 16 ). Consequently, the TERT promoter target region was amplified via PCR using the following primer pair: TERT promoter forward 5′-CAGCGCTGCCTGAAACTC−3′; reverse 5′-GTCCTGCCCCTTCACCTT−3′ ( 1 , 2 ). Consequently, the TERT promoter target region was amplified via PCR using the following primer pair: TERT promoter forward 5′CAGCGCTGCCTGAAACTC3′; reverse 5′GTCCTGCCCCTTCACCTT3′ and the following reagents mixture: 10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl 2 (pH 8.3), 0.2 mM dNTPs, 8 pmol primers and 1.25 U AmpliTaq Gold DNA Polymerase (Thermo Fisher Scientific, Inc.) in a final volume of 20 µl.…”

Section: Methodsmentioning

confidence: 99%

“…Papillary thyroid carcinoma (PTC) is the most common type of endocrine malignancy ( 1 ). PTC accounts for ~80% of thyroid carcinomas in adults and 90% in children; patients are usually 20–50 years old, but individuals of any age may be affected ( 1 ). PTC is more common in females, with a prevalence 2.9-times higher in women than in men ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases

et al. 2017

View full text Add to dashboard Cite

Papillary thyroid carcinoma (PTC) is the most common type of endocrine malignancy and accounts for ~80% of thyroid carcinomas in adults and 90% in children. Risk stratification is important for identifying patients at higher risk and, for this reason, recent advances in molecular genetics of thyroid cancer can be applied to provide novel biomarkers useful in understanding tumor behavior. B-Raf proto-oncogene, serine/threonine kinase (BRAF) and rat sarcoma (RAS) mutations have been widely studied and appear to have an important role in thyroid tumorigenesis. Somatic telomerase reverse transcriptase (TERT) promoter mutations have been recently identified in several types of malignant tumors, including thyroid neoplasia; however, the actual role of TERT mutations in thyroid tumorigenesis is still under debate. In the present study, the mutational status of BRAF, RAS and TERT was analyzed in order to elucidate the roles of these genes in thyroid tumorigenesis. The TERT mutational analysis was also correlated with an immunohistochemical study of TERT protein expression. According to the literature, our data provide evidence of the BRAF and RAS roles in thyroid tumorigenesis, supporting an association between BRAF (V600E) mutations and the more aggressive clinical and pathological features of thyroid tumors. By contrast, TERT mutations were not significantly associated with any clinical parameters; therefore, its role in initial tumorigenesis should be further investigated.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases

et al. 2017

View full text Add to dashboard Cite

show abstract

Integrated analysis identifying new lncRNA markers revealed in ceRNA network for tumor recurrence in papillary thyroid carcinoma and build of nomogram

Chen

Deng

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Object: The risk of tumor recurrence is currently the focus of clinical attention in the treatment of papillary thyroid carcinoma (PTC). This study focuses on the identification of novel prognostic long noncoding RNA (lncRNA) signatures for tumor recurrence in PTC.Method: RNA sequencing profiling of patients with PTC was obtained from the TCGA and Gene Expression Omnibus databases. Differently expressed lncRNA, microRNA (miRNA), and messenger RNA (mRNA) signatures between patients with and without tumor recurrence were selected. The lncRNA-miRNA-mRNA competing endogenous RNA (ceRNA) network for tumor recurrence in PTC was constructed to identify lncRNAs associated with tumor relapse in papillary carcinoma. Functional enrichment analysis was performed. Adjusted odds ratios were estimated to identify candidate prognostic lncRNAs considering clinical covariates. Validation analysis was conducted. Nomogram was built based on the verified prognostic lncRNAs and clinical features. Results:The lncRNA-miRNA-mRNA ceRNA network for tumor recurrence in PTC was constructed. Functional enrichment analysis suggested that the identified lncRNAs were associated with PTC. Adjusted odds ratios indicated that 5 of the 16 selected lncRNAs were candidate biomarkers predicting tumor recurrence of thyroid carcinoma. Among which, TTTY10 was verified as novel prognostic markers in validation analysis. Nomogram was built based on the newly identified lncRNA biomarker and clinical covariates.Conclusion: In this study, lncRNA TTTY10 was identified as potential novel prognostic markers predicting tumor recurrence in PTC. It may provide useful information for future molecular and cohort studies focusing on the prognosis of PTC. K E Y W O R D SceRNA network, lncRNA, nomogram, papillary thyroid carcinoma, tumor recurrence

show abstract

Papillary Thyroid Carcinoma

Cited by 2 publications

References 68 publications

TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases

TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases

Integrated analysis identifying new lncRNA markers revealed in ceRNA network for tumor recurrence in papillary thyroid carcinoma and build of nomogram

Contact Info

Product

Resources

About